20 June 2020 : Database Analysis
Special AT-rich Sequence Binding-Protein 1 (SATB1) Correlates with Immune Infiltration in Breast, Head and Neck, and Prostate Cancer
Hua Ge1ABCDEF*, Yan Yan2BCDE, Maozhao Yan1CEF, Lingfei Guo1EF, Kun Mao1CFDOI: 10.12659/MSM.923208
Med Sci Monit 2020; 26:e923208
Table 2 Correlation of SATB1 expression with prognostic values in diverse types of cancer in GEPIA.
| Cancer type | Overall survival | Disease free survival | ||
|---|---|---|---|---|
| HR | P | HR | P | |
| ACC | 0.93 | 0.85 | 1.3 | 0.47 |
| BLCA | 0.78 | 0.098 | 1.0 | 0.87 |
| BRCA | 0.95 | 0.75 | 0.99 | 0.98 |
| CESC | 1.1 | 0.82 | 1.2 | 0.48 |
| CHOL | 0.61 | 0.33 | 0.45 | 0.091 |
| COAD | 1.0 | 1 | 1.1 | 0.73 |
| DLBC | 1.4 | 0.64 | 1.5 | 0.54 |
| ESCA | 0.81 | 0.37 | 1.2 | 0.48 |
| GBM | 1.3 | 0.13 | 0.81 | 0.32 |
| HNSC | 0.82 | 0.15 | 0.73 | 0.061 |
| KICH | 2.8 | 0.19 | 1.3 | 0.7 |
| KIRC | 0.58 | 0.00065 | 0.57 | 0.0026 |
| KIRP | 0.95 | 0.87 | 0.7 | 0.23 |
| LAML | 1.2 | 0.44 | 1 | 1 |
| LGG | 0.49 | 0.00011 | 0.64 | 0.0049 |
| LIHC | 0.91 | 0.58 | 0.94 | 0.66 |
| LUAD | 0.78 | 0.095 | 1.1 | 0.6 |
| LUSC | 0.84 | 0.22 | 0.81 | 0.25 |
| MESO | 0.95 | 0.8 | 0.77 | 0.34 |
| OV | 1.1 | 0.27 | 1.2 | 0.19 |
| PAAD | 0.76 | 0.18 | 1.2 | 0.44 |
| PCPG | 1.8 | 0.52 | 0.39 | 0.09 |
| PRAD | 1.8 | 0.36 | 0.56 | 0.0075 |
| READ | 0.77 | 0.58 | 2.1 | 0.14 |
| SARC | 1.6 | 0.023 | 1.4 | 0.092 |
| SKCM | 0.54 | 5.8e-06 | 0.72 | 0.0076 |
| STAD | 0.91 | 0.56 | 1.5 | 0.039 |
| TGCT | 0.43 | 0.46 | 0.65 | 0.24 |
| THCA | 0.58 | 0.28 | 1.2 | 0.48 |
| THYM | 0.28 | 0.096 | 0.58 | 0.24 |
| UCEC | 1 | 0.98 | 0.9 | 0.74 |
| UCS | 0.52 | 0.062 | 0.52 | 0.076 |
| UVM | 0.13 | 0.00016 | 0.31 | 0.021 |
| GEPIA – Gene Expression Profiling Interactive Analysis; HR – hazard ratio; CI – confidence interval; ACC – adenoid cystic carcinoma; BLCA – bladder urothelial carcinoma; BRCA – breast invasive carcinoma; CESC – cervical squamous cell carcinoma; CHOL – cholangiocarcinoma; COAD – colon adenocarcinoma; DLBC – diffuse large B-cell lymphoma; ESCA – esophageal carcinoma; GBM – glioblastoma; HNSC – head and neck cancer; KICH – kidney chromophobe; KIRC – kidney renal clear cell carcinoma; KIRP – kidney renal papillary cell carcinoma; LAML – lymphoblastic acute myeloid leukemia; LGG – low-grade gliomas; LIHC – liver hepatocellular carcinoma; LUAD – lung adenocarcinoma; LUSC – lung squamous cell carcinoma; MESO – mesothelioma; OV – ovarian; PAAD – pancreatic adenocarcinoma; PCPG – paraganglioma; PRAD – prostate adenocarcinoma; READ – rectum adenocarcinoma; SARC – sarcoma; SKCM – skin cutaneous melanoma; STAD – stomach adenocarcinoma; TGCT – testicular germ cell tumors; THCA – thyroid carcinoma; THYM – thymoma; UCEC – uterine corpus endometrial carcinoma; UCS – uterine carcinosarcoma; UVM – uveal melanoma. | ||||